Slingshot members are tracking this event:

Ionis Pharma (IONS) to complete Phase 3 study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients with Familial Chylomicronemia Syndrome in March 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 06, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Volanesorsen, Ionis-apociiirx, Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia